Aerovate Therapeutics Inc
NASDAQ:AVTE
Aerovate Therapeutics Inc
Cash from Investing Activities
Aerovate Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
Cash from Investing Activities
$11.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Aerovate Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
11.9m
USD
Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Cash from Investing Activities amounts to 11.9m USD.
What is Aerovate Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
71%
Over the last year, the Cash from Investing Activities growth was 71%.